Nilotinib (AMN107)

DRUG2 trials

Sponsors

Novartis Pharmaceuticals

Conditions

Gastrointestinal Stromal Tumor (GIST)Myelogenous Leukemia

Phase 3

Nilotinib vs Imatinib in Adult Patients With Philadelphia (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)

TerminatedNCT00519090

Novartis PharmaceuticalsMyelogenous Leukemia

Start: 2007-10-31End: 2008-10-31Updated: 2011-11-07

A Study of Nilotinib Versus Imatinib in GIST Patients

CompletedNCT00785785

Novartis PharmaceuticalsGastrointestinal Stromal Tumor (GIST)

Start: 2009-03-31End: 2014-10-31Updated: 2016-06-16

Related Papers

Nilotinib versus imatinib as first-line therapy for patients with unresectable or metastatic gastrointestinal stromal tumours (ENESTg1): a randomised phase 3 trial.

2015-04-1484 citations